*************** WTF ***************
Carter Ward
Mirror Biologics, Inc. - CFO
Sep 2022 - Present - 3 months
Enveric Biosciences - CFO
May 2021 - Sep 2022 - 1 year 5 months
Elite Pharmaceuticals - CFO
Jul 2009 - May 2021 - 11 years 11 months
FULL PRESS RELEASE:
August 19, 2022 -- Mirror Biologics, Inc. (“Mirror”), a clinical stage biopharmaceutical company today announced the appointment of Carter J. Ward as Chief Financial Officer, effective September 12, 2022.
“Mr. Ward joins the Mirror team with the experience and hands-on financial leadership at just the right time as we enter a phase in our development which is expected to be characterized by rapid growth and strategic inflection points,” said Dr. Michael Har-Noy, Mirror’s founder and Acting CEO. “Carter’s background leading life science companies from startup through to commercialization, combined with extensive SEC reporting and capital market experience will be a key ingredient in achieving our goal of providing effective and economical living cell immunotherapy treatments on a global basis.”
Mr. Ward has over 30 years of industry experience after starting his career at KPMG and most recently served as CFO at Enveric Biosciences (NASDAQ), a biotechnology company developing psychedelic-derived pharmaceuticals to treat mental ailments stemming from cancer and other conditions. During his tenure at Enveric, Mr. Ward successfully negotiated and executed capital raises, provided financial leadership for M&A activities, created in-house reporting functionality and supported the development of strategic initiatives with financial and operational modeling.
Before joining Enveric, Mr. Ward served as CFO of Elite Pharmaceuticals (OTC), where he also negotiated and executed capital raises, created financial reporting functions, developed strategic initiatives and provided financial and supply chain leadership as Elite transformed from a clinical stage biotechnology company to a commercial pharmaceutical manufacturer.
Additionally, Mr. Ward’s earlier experience includes finance and supply chain roles at Actavis USA and international finance experience with Ceejay Healthcare in India and Petro Pharma Pte. Ltd. in Singapore.
“Biologics is the future, and the Mirror technology platform and manufacturing pods are at the cutting edge of the biologics revolution,” stated Mr. Ward. “I’m honored to have this opportunity to join the Mirror team and believe the late stage clinical assets and pipeline show such potential to restore quality of life to patients with cancer and infectious diseases. I look forward to playing a significant role in Mirror’s legacy by establishing a world class financial function and helping to guide Mirror from development to commercialization and global success.”
-------------------------------------------------------------------------------------------------------------------------------------
AI
